Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s): ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

TSX:ATE - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Canaccord Genuity managers seek to take firm private

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Jan 09, 2023 1:59pm

145 Views

Post# 35211620

RE:RE:Canaccord Genuity managers seek to take firm private

MrMugsy wrote:
Forestview wrote: Article below. Anyone see an impact on Antibe as a result?

https://financialpost.com/fp-finance/canaccord-genuity-managers-take-firm-private-1-13-billion

Canaccord Genuity Group Inc.’s management group is seeking to take the firm private in a $1.13-billion deal, taking advantage of a plunge in the share price after last year’s turmoil in capital markets.

The management group — which includes the firm’s chief executive, chair and more than a dozen other senior executives — owns a combined 21 per cent of the shares, the group said in a statement on Monday. Canaccord’s largest outside shareholder also supports the bid of $11.25 per share, according to the statement.

Canaccord’s stock has fallen by 48 per cent since a pandemic-era peak in November 2021, as volatile markets and plunging global equity prices put a chill in the initial public offerings and other transactions the firm specializes in. The deal would return the company — which was founded as a regional brokerage in 1950 — to private markets after 18 years.

“The common shares, which naturally reflect the inherent volatility of the global capital markets in which the company operates, have proven to be not well-suited for trading in a public marketplace,” chief executive Dan Daviau said in the statement. “As an employee-owned business, the company will be able to focus its efforts solely on advancing its proven strategies in ways that serve the best interests of its clients.”

Not at all Forestview.

I am very glad that ATE is public and I don't think they're looking to change that.

Money-managing is also very different than what we're doing. They don't have the same luxury of huge spikes on P2 data results and then spikes on P3 partnering.

The only similarity is ... that the buyers had al vanished for a wee bit before P2. That was our buying queue !!!!